News | May 01, 2026
Fabtech Technologies FY26 revenue rises 28% to Rs 431 crore
Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets
Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
Analysts expect modest revenue growth but pressure on profitability in the March quarter
Muted movement reflects consolidation phase as investors await earnings triggers
The company allocated €56 million to research and development for next-generation line solutions
The company reported net revenue of SEK 13.5 million for the full year 2025
Subscribe To Our Newsletter & Stay Updated
